Apnea of Prematurity Clinical Trial
Official title:
A Prospective, Controlled Trial of Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea of Prematurity
Verified date | February 2015 |
Source | University of Manitoba |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Ethics Review Committee |
Study type | Interventional |
In premature infants, apnea of prematurity is one of their major clinical problems. Caffeine is currently a worldwide therapy to reduce the number and severity of these apneas. This practice has shown to be safe on cognitive and neurodevelopmental outcomes at 18 to 21 months of age. However, caffeine is not 100% effective, and may have little effect on hypoxemia and bradycardia. Infants with intractable apneas unresponsive to caffeine treatment may require endotracheal intubation and mechanical ventilation. This procedure is invasive and has been associated with complications and increased risk for chronic lung disease and adverse neurodevelopmental outcome. Therefore, an alternative treatment modality would be preferable if it would prevent the infants from requiring endotracheal intubation. The investigators have been testing the overall hypothesis that small concentrations of inhaled CO2 (~1%) are effective in treating apnea of prematurity. The investigators have completed three studies in preterm infants showing that inhalation of low concentration of CO2, in infants not on caffeine, regularize breathing and decrease apneas significantly. The effects of inhalation of CO2 in infants already on caffeine, are unknown. The hypothesis to be tested is that inhalation of low concentration CO2 (1%) will significantly reduce apnea in infants treated with caffeine. The investigators have three specific aims in this proposal. 1) the investigators want to know if the apnea rate (number of apneas of ≥5 seconds/hour) is decreased with CO2 inhalation in preterm infants already on caffeine for the treatment of apnea of prematurity; 2) the investigators want to know whether inhalation of CO2 can make breathing more regular with less apneic time and whether it decreases prolonged apneas (>20 seconds) in infants already on caffeine for the treatment of apnea of prematurity; 3) the investigators want to assess the effect of inhalation of low concentration of CO2 on the regional oxygen saturation of the brain measured by near-infrared spectroscopy (NIRS) during apneas. This is to see whether CO2, by protecting cerebral blood flow, minimizes the decrease in cerebral oxygenation during apneas. This study entails a new and possibly more physiological method of treating apneas of prematurity that can be added to the present treatment of caffeine. These two treatments together, could minimize the number and severity of apneas and possibly decrease the need for mechanical ventilation in preterm infants.
Status | Terminated |
Enrollment | 7 |
Est. completion date | July 2014 |
Est. primary completion date | July 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A to 60 Days |
Eligibility |
Inclusion Criteria: - gestational age at birth < 33 weeks - on caffeine treatment for apnea of prematurity at a maintenance dose of 5 mg/kg/day - having apnea of prematurity (at least 5 self-resolved apneas or 2 apneas requiring intervention/12 hours) Exclusion Criteria: - on mechanical ventilation - presence of congenital anomalies, sepsis or other known causes of apnea - failure to obtain parental consent |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | University of Manitoba | Winnipeg | Manitoba |
Lead Sponsor | Collaborator |
---|---|
University of Manitoba | Manitoba Institute of Child Health |
Canada,
Al-Aif S, Alvaro R, Manfreda J, Kwiatkowski K, Cates D, Rigatto H. Inhalation of low (0.5%-1.5%) CO2 as a potential treatment for apnea of prematurity. Semin Perinatol. 2001 Apr;25(2):100-6. — View Citation
Al-Saif S, Alvaro R, Manfreda J, Kwiatkowski K, Cates D, Qurashi M, Rigatto H. A randomized controlled trial of theophylline versus CO2 inhalation for treating apnea of prematurity. J Pediatr. 2008 Oct;153(4):513-8. doi: 10.1016/j.jpeds.2008.04.025. Epub 2008 Jun 4. — View Citation
Alvaro RE, Khalil M, Qurashi M, Al-Saif S, Al-Matary A, Chiu A, Minski J, Manfreda J, Kwiatkowski K, Cates D, Rigatto H. CO(2) inhalation as a treatment for apnea of prematurity: a randomized double-blind controlled trial. J Pediatr. 2012 Feb;160(2):252-257.e1. doi: 10.1016/j.jpeds.2011.07.049. Epub 2011 Sep 9. — View Citation
Davis PG, Schmidt B, Roberts RS, Doyle LW, Asztalos E, Haslam R, Sinha S, Tin W; Caffeine for Apnea of Prematurity Trial Group. Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. J Pediatr. 2010 Mar;156(3):382-7. doi: 10.1016/j.jpeds.2009.09.069. Epub 2009 Nov 18. — View Citation
Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W; Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006 May 18;354(20):2112-21. — View Citation
Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W; Caffeine for Apnea of Prematurity Trial Group. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007 Nov 8;357(19):1893-902. — View Citation
Schmidt B, Roberts RS, Davis P, Doyle LW; Steering Committee of the Caffeine for Apnea of Prematurity (CAP) trial. Archimedes: Does caffeine treatment for apnoea of prematurity improve neurodevelopmental outcome in later life? Arch Dis Child. 2011 Aug;96(8):784. doi: 10.1136/adc.2010.206698. Epub 2011 Mar 4. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effect of inhalation of low concentration of CO2 (1%) on the apnea rate (number of apneas of =5 seconds/hour) in preterm infants already on caffeine for the treatment of apnea of prematurity. | 3 hours | Yes | |
Secondary | Effect of low concentration of CO2 on apneic time in seconds per hour and duration of long apneas in seconds | 3 hours | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03670732 -
CPAP vs.Unsynchronized NIPPV at Equal Mean Airway Pressure
|
N/A | |
Terminated |
NCT02524249 -
Early Versus Late Caffeine for ELBW Newborns
|
N/A | |
Completed |
NCT03292562 -
A Comparison of Methods of Discontinuing Nasal CPAP in Premature Infants <30 Weeks Gestation
|
N/A | |
Recruiting |
NCT05298748 -
The Effect of Womb Recordings on Maturation of Respiratory Control in Preterm Infants
|
N/A | |
Recruiting |
NCT05968586 -
Non-Invasive Neurally Adjusted Ventilatory Assist (NAVA) Prone vs Supine in Premature Infants
|
N/A | |
Active, not recruiting |
NCT02641249 -
Non-invasive Intervention for Apnea of Prematurity
|
N/A | |
Completed |
NCT00182312 -
Caffeine for Apnea of Prematurity (CAP)
|
Phase 3 | |
Recruiting |
NCT03651648 -
Apnea Treatment in Premature Infants Using an Automatic Vibro-tactile Stimulator Triggered by the Detection of Apnea-bradycardia.
|
N/A | |
Recruiting |
NCT03298347 -
Caffeine for Preterm Infants With Apnea of Prematurity(AOP)
|
N/A | |
Completed |
NCT01020357 -
Caffeine for Apnea of Prematurity-Sleep (CAP-S) Study
|
Phase 3 | |
Completed |
NCT00809055 -
MRI and Neurodevelopment in Preterm Infants Following Administration of High-Dose Caffeine
|
Phase 4 | |
Completed |
NCT03298035 -
A Comparison of Non-invasive Ventilation Methods Used to Prevent Endotracheal Intubation Due to Apnea in Very Low Birth Weight Infants
|
N/A | |
Completed |
NCT03695900 -
Arterial Oxygen Saturation on Ventilatory Stability in Extremely Premature Infants
|
N/A | |
Completed |
NCT04327466 -
Effect of High Frequency Oscillatory Highflow Nasal Cannula on Desaturations and Bradycardia in Preterm Infants
|
N/A | |
Not yet recruiting |
NCT06374147 -
"Prapela® SVS Incubator Pad for Apnea of Prematurity
|
N/A | |
Completed |
NCT04868565 -
Target Weaning Oxygen to Determine Cafffeine Duration for AOP
|
Phase 4 | |
Terminated |
NCT00482040 -
Randomized Trial Investigating Four Nasal CPAP Systems in the Management of Apnea of Prematurity
|
N/A | |
Not yet recruiting |
NCT06292299 -
The PARS Study: Paediatric Advanced Respiratory Service Study - An Observational Diagnostic Feasibility Study
|
||
Completed |
NCT05393817 -
Caffeine Citrate Use and Electronic Activity of the Diaphragm (EDI) Changes
|
||
Recruiting |
NCT04430790 -
Doxapram Therapy in Preterm Infants (DOXA Trial)
|
Phase 3 |